Search research articles
Contact Us
Filters
Showing results (121-130 of 138) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Hansol Lee, Angela L Ferguson, Camelia Quek, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Cancer Discovery
|
January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
Tiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
Nature Communications
|
February 28, 2013
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Yan Ye, Lei Jin, James S Wilmott, et al.
Cancer Cell
|
June 18, 2021
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Oskar Marin-Bejar, Aljosja Rogiers, Michael Dewaele, et al.
Cancer Cell
|
February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N Gide, Camelia Quek, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 138) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Hansol Lee, Angela L Ferguson, Camelia Quek, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Cancer Discovery
|
January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
Tiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
Nature Communications
|
February 28, 2013
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Yan Ye, Lei Jin, James S Wilmott, et al.
Cancer Cell
|
June 18, 2021
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Oskar Marin-Bejar, Aljosja Rogiers, Michael Dewaele, et al.
Cancer Cell
|
February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N Gide, Camelia Quek, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Page
of 14